Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31258190 | 0.86 | USP30 (0.40) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL31258189 | 0.85 | UCHL1 (0.40) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL31710740 | 0.83 | USP30 (0.39) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL3709336 | 0.78 | USP30 (0.38) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL29821684 | 0.78 | USP30 (0.38) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL30293091 | 0.77 | USP30 (0.39) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL22438298 | 0.77 | USP30 (0.39) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL1359746 | 0.77 | USP30 (0.49) | USP30 | |
| SCHEMBL29339990 | 0.76 | USP30 (0.52) | USP30 | |
| SCHEMBL15412342 | 0.76 | USP30 (0.40) | UCHL1USP30ELANEFFAR1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053215-B2 | Heterocyclic compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2021-07-06 | — | — | US | disclosed |
| US-10450296-B2 | Heterocyclic compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180282302-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2018-10-04 | — | — | US | disclosed |
| US-9920032-B2 | Heterocyclic compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170096411-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282302-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | UCHL1 3737/4885USP30 3601/4885ELANE 4454/4885 |
| US-11053215-B2 | Heterocyclic compounds useful as Pim kinase inhibitors | PIM1, PIM2, PIM3 | UCHL1 3737/4885USP30 3601/4885ELANE 4454/4885 |
| US-10450296-B2 | Heterocyclic compounds useful as Pim kinase inhibitors | PIM1, PIM2, PIM3 | UCHL1 3737/4885USP30 3601/4885ELANE 4454/4885 |
| US-20170096411-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | UCHL1 3737/4885USP30 3601/4885ELANE 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.